Abstracts tagged "rheumatoid arthritis"

Abstract Number: 0457 • ACR Convergence 2024
Metabolic Syndrome, Adipokines, and Response to Advanced Therapies in Rheumatoid Arthritis
Joshua Baker¹, George Reed², Geoffrey Thiele³, Dimitrios Pappas⁴, christina Charles-Schoeman⁵, Monica Guma⁶, Leslie Harrold⁷, Jeffrey Curtis⁸ and Joel Kremer⁹, ¹Department of Medicine, Perelman School of Medicine University of Pennsylvania, Philadelphia, PA, ²University of Massachusetts Chan Medical School, Worcester, MA, ³University of Nebraska Medical Center, Omaha, NE, ⁴CorEvitas, New York, NY, ⁵UCLA Medical Center, Santa Monica, CA, ⁶UCSD, La Jolla, CA, ⁷CorEvitas, Northborough, MA, ⁸University of Alabama at Birmingham, Hoover, AL, ⁹The Corrona Research Foundation, Delray Beach, FL
Background/Purpose: While BMI has been associated with response to therapy in several studies in rheumatoid arthritis (RA), it is not a comprehensive measure of the…
Abstract Number: 0473 • ACR Convergence 2024
Immune Checkpoint–Induced Arthritis: A Comprehensive Single Cohort Descriptive Analysis from Clinical Evaluation to Histology
NATALUCCI Francesco¹, SOKOLOVA Tatiana², NZEUSSEU TOUKAP Adrien³, GALANT Christine⁴, ABOUBAKAR Frank⁵, BAURAIN Jean-François⁶, CORNELIS Frank⁶, BORBATH Yvan⁷, DUREZ Patrick² and MERIC de BELLEFON Laurent², ¹Sapienza University of Roma, Rheumatology, Department of Clinical, Internistic, Anesthesiological and cardiovascular sciences, Roma, Italy, ²Cliniques Universitaires Saint-Luc – Université catholique de Louvain (UCLouvain) – Institut de Recherche Expérimentale et Clinique (IREC), Rheumatology, Brussels, Belgium, ³Institut de Recherche Expérimentale et Clinique, Cliniques universitaires Saint-Luc, Université catholique de Louvain, St.-Lambrechts-Woluwe, Belgium, ⁴Department of Pathological Anatomy, Cliniques Universitaires Saint-Luc, Brussels, Belgium, ⁵Division of Pneumology, Cliniques Universitaires Saint-Luc, Brussels, Brussels, Belgium, ⁶Medical Oncology Department, Université Catholique de Louvain and Cliniques Universitaires Saint-Luc, Brussels, Belgium, ⁷Department of Hepato-gastroenterology, Cliniques Universitaires St Luc, Brussels, Belgium
Background/Purpose: The increasing use of Immune Check-Point Inhibitors (ICIs) to treat malignancy focused attention on immune-related adverse events (irAEs). ICIs-induced arthritis is the most common…
Abstract Number: 0491 • ACR Convergence 2024
Small Molecule Metabolites, Potential Disease-specific Biomarkers for Predicting Treatment Response in Rheumatoid Arthritis
Jiayi Xu¹, Yi Zhao², Chenxi Zhu³, Yi Liu⁴, Tao Chen¹, Rui Sun³, Huifang Hu⁵, Zhen Zhou¹ and Yan Liu¹, ¹Department of Rheumatology and Immunology, West China Hospital,Sichuan University, Chengdu, Sichuan, China, Cheng du, China (People's Republic), ²Department of Rheumatology and Immunology, West China Hospital,Sichuan University, Chengdu, Sichuan, China, Sichuan, China (People's Republic), ³Department of Rheumatology and Immunology, West China Hospital,Sichuan University, Chengdu, Sichuan, China, chengdu, China (People's Republic), ⁴Department of Rheumatology and Immunology, West China Hospital,Sichuan University, Chengdu, Sichuan, China, chengdu, ⁵Department of Rheumatology and Immunology, West China Hospital,Sichuan University, Chengdu, Sichuan, China, Chengdu, Sichuan, China (People's Republic)
Background/Purpose: Rheumatoid arthritis (RA) is a complex chronic inflammatory condition primarily affecting joints, presenting a challenge in understanding its causes, varied subtypes, diagnostic indicators, and…
Abstract Number: 0507 • ACR Convergence 2024
Neutrophil Activation Markers Can Predict Rheumatoid Arthritis Treatment Response to the Janus Kinase 1/2 Inhibitor Baricitinib
Runa Kuley¹, Bhargavi Duvvuri¹, Sabeeha Hasnain², Ernst Dow³, Alisa Koch⁴, Richard Higgs⁴, Venkatesh Krishnan⁴ and Christian Lood⁵, ¹University of Washington, Seattle, ²Mahindra University, Hyderabad, India, ³Eli Lilly and Co, Indianapolis, IN, ⁴Eli Lilly, Indianapolis, IN, ⁵University of Washington, Seattle, WA
Background/Purpose: Neutrophils play an important role in regulating immune and inflammatory responses in rheumatoid arthritis (RA). We assessed whether baricitinib, a JAK1/JAK2 inhibitor, could reduce…
Abstract Number: 0524 • ACR Convergence 2024
Evaluating Dose Reduction of Biologic Treatments in Rheumatoid Arthritis: Predicting Flares Using Clinical and Molecular Biomarkers
Laura Galindo Domínguez¹, Belen Acasuso², Vanesa Balboa-Barreiro³, Juan Fernández-Tajes², Juan Cañete⁴, Benjamin Fernández-Gutiérrez⁵, Isidoro González-Álvaro⁶, José L Pablos⁷, Carmen Bejerano-Herreria⁸, Maite Silva-Díaz⁹, Franciso javier De-Toro-Santos², Natividad Oreiro¹⁰ and francisco J Blanco¹¹, ¹Instituto de Investigacion Biomedica de A Coruña (INIBIC), A Coruña, Spain, ²Unidad de Investigacion Clinica. Grupo de Investigación de Reumatología (GIR). Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas., Investigation, A Coruña, Spain, A Coruña, Spain, ³Unidad de Epidemiología Clínica y Bioeostadística. Instituto de Investigación Biomédica de A Coruña (INIBIC). Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas. Universidade da Coruña (UDC)., A Coruña, Spain, ⁴Hospital Clinic an IDIBAPS, Barcelona, Spain, ⁵3Rheumatology Department, and Health Research Institute (IdISSC), Hospital Clínico San Carlos, Calle del Profesor Martín Lagos, s/n, 28040, Madrid, Spain., Rheumatology, Madrir, Spain, Madrid, Madrid, Spain, ⁶University Hospital La Princesa, Madrid, Madrid, Spain, ⁷Health ministry, Madrid, Madrid, Spain, ⁸Hospital Universitario Marqués de Valdecilla, Santander, Spain, ⁹Complejo Hospitalario Universitario de A Coruña, A Coruña, Spain, ¹⁰CHUAC, La Coruna, Galicia, Spain, ¹¹INIBIC-University of A Coruña, A Coruña, Spain
Background/Purpose: Reducing the dosage of biologic drugs in patients with rheumatoid arthritis (RA) who have achieved remission is a viable and necessary strategy. To identify…
Abstract Number: 0794 • ACR Convergence 2024
Social Security Work Disability and Its Predictors in Patients with Fibromyalgia: 25 Years of Followup
Shreena Kamlesh Gandhi¹, Sofia Pedro², Brian Walitt³, Winfried Häuser⁴, Robert Katz⁵ and Kaleb Michaud⁶, ¹KU School of Medicine, Wichita, Wichita, KS, ²Forward, The National Databank for Rheumatic Diseases, Wichita, KS, ³NIH, Bethesda, MD, ⁴Klinikum Saarbrücken Germany, Munich, Germany, ⁵Rush University Medical Center, Chicago, IL, ⁶University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Disability benefits are crucial for individuals unable to work due to debilitating medical conditions, commonly facilitated through programs like Social Security Disability Insurance (SSD)…
Abstract Number: 0873 • ACR Convergence 2024
Epigenetic Control of Pathogenic CD4 T Cell Polarization During Progression to Rheumatoid Arthritis (RA)
Ziyuan He¹, Pravina Venkatesan¹, Adam Savage¹, Marla Glass¹, Lauren Okada², Upaasana Krishnan², Christy Bennett¹, Nhung Tran², Yudong He², Samir Rachid Zaim¹, Padmapriyadarshini Ravisankar², Jessica Garber², Palak Genge², Kevin Lee², Regina Mettey², Cole Phalen², Sugandhika Khosa², Marie Feser³, Fan Zhang⁴, David Boyle⁵, Kristine Kuhn⁴, Kristen Demoruelle⁶, Cate Speake⁷, Jane Buckner⁸, Ananda Goldrath¹, Thomas Bumol⁹, V. Michael Holers¹⁰, Peter Skene¹, Gary Firestein¹¹, Xiaojun Li¹, Kevin Deane¹², Troy Torgerson¹³ and Mark Gillespie¹, ¹Allen Institute for Immunology, Seattle, WA, ²Allen Institute for Immunology, Seattle, ³Division of Rheumatology, University of Colorado School of Medicine, Aurora, CO, ⁴University of Colorado, Aurora, CO, ⁵UCSD, La Jolla, CA, ⁶University of Colorado Anschutz Medical Campus, Golden, CO, ⁷Benaroya Research Institute at Virginia Mason, Seattle, ⁸Benaroya Research Institute, Seattle, WA, ⁹Allen Institute for Immunology, San Diego, CA, ¹⁰University of Colorado, Denver, CO, ¹¹University of California, San Diego, San Diego, CA, ¹²University of Colorado Denver Anschutz Medical Campus, Aurora, CO, ¹³Allen Institute for Immunology, Enumclaw, WA
Background/Purpose: Multiple T cell subsets, including Th1, Th17 cells, and Tfh/Tph, contribute to rheumatoid arthritis (RA) pathology. Clinical trials have shown efficacy of T cell…
Abstract Number: 0939 • ACR Convergence 2024
A Joint-targeting Peptide Enhances the Therapeutic Efficacy of Liposomal Drug Delivery in Experimental Rheumatoid Arthritis
Hemalatha Nanjaiah, Rakeshchandra Meka, Bodhraj Acharya, Shivaprasad Venkatesha and Kamal Moudgil, University of Maryland School of Medicine, Baltimore, Baltimore, MD
Background/Purpose: Rheumatoid arthritis (RA) is a chronic autoimmune disease of synovial joints, and it affects over 1 per cent of the population worldwide. Uncontrolled or…
Abstract Number: 0993 • ACR Convergence 2024
Pulmonary Complications and Mortality Trends in Rheumatoid Arthritis Patients Aged 65 and Older in the United States: A CDC WONDER Database Analysis
Muhammad Naveed¹, Rabia Iqbal¹, Kishan Patel², Ahila Ali¹, Simran Bhimani³, Bazil Azeem⁴, Yash Deshpande³, Muhammad Omer Rehan¹, Faizan Ahmed⁵, Hussain Haider Shah¹ and Nouman Shafique⁶, ¹Dow Medical College, Dow University of Health Sciences, Karachi, Pakistan, ²Riverside Community Hospital, Riverside, CA, ³The Wright Center for graduate medical education, Scranton, PA, ⁴Shaheed Mohtarma Benazir Bhutto Medical College Liyari, Karachi, Pakistan, ⁵Ameer-ud-Din Medical College, Lahore, Pakistan, ⁶AdventHealth Orlando, Orlando, FL
Background/Purpose: Pulmonary complications in rheumatoid arthritis (RA) are an important cause of mortality among older adults. This study analyzes trends and demographic disparities in mortality…
Abstract Number: 1045 • ACR Convergence 2024
Impact of Stable Rheumatologic Therapy on Outcomes of Depression in Members with Rheumatoid Arthritis, Psoriatic Arthritis, and Systemic Lupus Erythematosus
Jean Park¹, Cliff Rutter², Elisea Avalos-Reyes³, Mary Anderson⁴, Will Cavers⁵, Dorothea Verbrugge⁶ and Kjel Johnson⁷, ¹CVS Health, Hartford, CT, ²CVS Health, Fair Oaks Ranch, TX, ³CVS Health, Highland Village, TX, ⁴CVS Health, Irving, TX, ⁵CVS Health, Palm Beach Gardens, ⁶CVS Health, Salt Lake City, ⁷CVS Health, Tampa
Background/Purpose: Rheumatic diseases, such as rheumatoid arthritis (RA), psoriatic arthritis (PA), and systemic lupus erythematosus (SLE) can significantly impact quality of life. This burden extends…
Abstract Number: 1296 • ACR Convergence 2024
Effectiveness of Inflammatory Arthritides Educational Modules and Potential for Improved Referral Times
Christine Kim¹, Vincent Vertalino², Karen Kruzer³ and Allen Anandarajah⁴, ¹University of Rochester, Rochester, ²University of Rochester, Hamburg, NY, ³University of Rochester, Victor, NY, ⁴University of Rochester Medical Center, Rochester, NY
Background/Purpose: Early diagnosis and treatment of inflammatory arthritides [rheumatoid arthritis (RA), psoriatic arthritis (PsA) and ankylosing spondylitis (AS)] are associated with improved patient outcomes. However,…
Abstract Number: 1339 • ACR Convergence 2024
When Medications Fail: A Mixed Methods Study Evaluating the Experience and Health-Related Quality of Life (HRQOL) of Adults with Rheumatoid Arthritis Non-Responsive to Treatment
Kathleen Carluzzo¹, Erin Knight¹, Sidney May¹, Laura Bernstein², Kristen Mueller³, Clifton Bingham⁴ and Karen Schifferdecker¹, ¹Dartmouth College, Lebanon, NH, ²Dartmouth College, Philadelphia, PA, ³Arthritis Foundation, Washington, DC, ⁴Johns Hopkins University, Baltimore, MD
Background/Purpose: RA treatment involves an iterative approach to identifying effective medications for patients. While response varies, there is little in-depth understanding of patients’ perspectives of…
Abstract Number: 1355 • ACR Convergence 2024
Genetically-determined Variation in C-reactive Protein Impacts Disease Activity Assessment in Rheumatoid Arthritis
Thomas Riley¹, Austin Wheeler², grant Cannon³, Sauer brian⁴, Gary Kunkel⁵, Katherine Wysham⁶, Bryant England², Kristin Wipfler⁷, Kaleb Michaud², Beth Wallace⁸, Rachel Elam⁹, Paul Monach¹⁰, Andreas Reimold¹¹, Gail Kerr¹², Isaac Smith¹³, John Richards¹⁴, Iris Lee¹⁵, Michael March¹⁶, Scott Damrauer¹⁷, Anurag Verma¹⁷, Michael George¹⁷, Ted Mikuls² and Joshua Baker¹⁷, ¹Hopsital of the University of Pennsylvania, Philadelphia, PA, ²University of Nebraska Medical Center, Omaha, NE, ³University of Utah and Salt Lake City VA, Salt Lake City, UT, ⁴Salt Lake City VA/University of Utah, Salt Lake City, UT, ⁵University of Utah and George E Wahlen VAMC, Salt Lake City, UT, ⁶VA PUGET SOUND/UNIVERSITY OF WASHINGTON, Seattle, WA, ⁷FORWARD, The National Databank for Rheumatic Diseases, Omaha, NE, ⁸Michigan Medicine, VA Ann Arbor Healthcare System, Ann Arbor, MI, ⁹Augusta University, Evans, GA, ¹⁰VA Boston Healthcare System, Boston, MA, ¹¹Dallas VA Medical Center, Dallas, TX, ¹²Washington DC VAMC/Georgetown and Howard Universities, Washington, DC, ¹³Duke University Hospital, Durham, NC, ¹⁴Veterans Affairs Pittsburgh Healthcare System, Pittsburgh, PA, ¹⁵Washington University in St Louis, Saint Louis, MO, ¹⁶Children's Hospital of Philadelphia, Philadelphia, ¹⁷University of Pennsylvania, Philadelphia, PA
Background/Purpose: C-reactive protein (CRP) is often used as a biomarker for disease activity in patients with rheumatoid arthritis (RA). We evaluated whether rs1205, a common…
Abstract Number: 1371 • ACR Convergence 2024
DMARD Utilization Pattern in Older Adults with Rheumatoid Arthritis
Daniela Seelmann¹, Jiha Lee² and Devyani Misra³, ¹Beth Israel Deaconess Medical Canter, Newton, MA, ²University of Michigan, Ann Arbor, MI, ³Beth Israel Deaconess Medical Center, Boston, Boston, MA
Background/Purpose: Disease modifying anti-rheumatic drug (DMARD) use in older adults with rheumatoid arthritis (RA) is challenging due to unique geriatric issues, such as multimorbidity, polypharmacy,…
Abstract Number: 1388 • ACR Convergence 2024
CXC Chemokine Ligand 13 and Rheumatoid Factor as Pharmacodynamic Biomarkers for Abatacept Treatment in Patients with Rheumatoid Arthritis
Ting Wang¹, Ryan Stultz¹, Natalia Giltiay², Christian Lood¹ and Bobby Kwanghoon Han¹, ¹University of Washington, Seattle, WA, ²Division of Rheumatology, University of Washington, Seattle, USA, Seattle, WA
Background/Purpose: Abatacept, a CTLA-4-Ig fusion protein, is widely used as a treatment for rheumatoid arthritis (RA). We conducted this study to identify novel predictive and…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].